ReviewDementia & neuropsychologia
The economic cost of Alzheimer's disease: Family or public health burden?
Review in Dementia & neuropsychologia. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Pooled it
- Pooled it
- Trial
- Observational
- Gender differences in informal caregiving costs and burden in Alzheimer disease: a multinational cross-sectional analysis.BMC public health · 2026Article
- Estimating the Future Health and Social Care Costs of Alzheimer's Disease Dementia in the UK: Impact of Disease Modifying Therapy Efficacy, Uptake, and Care Model - A Scenario Modelling Study.International journal of geriatric psychiatry · 2026Article
- Protective Role of Holothuria leucospilota Extract Against Amyloid-β Toxicity via Autophagy and Antioxidant Mechanisms in Caenorhabditis elegans Model.Oxidative medicine and cellular longevity · 2026Article
- Stakeholder perceptions of dementia in Colombia: a qualitative study.BMC public health · 2025Article
- Olfactory EEG based Alzheimer disease classification through transformer based feature fusion with tunableFrontiers in neuroscience · 2025Article
- Dementia care from the perspective of family members, caregivers, and public health and social care professionals: a qualitative study of the Italian fund for Alzheimer's and other dementias.Frontiers in public health · 2025Article
- Chemical Characterization and Assessment of the Neuroprotective Potential ofInternational journal of molecular sciences · 2024Article
- Characterizing dysregulations via cell-cell communications in Alzheimer's brains using single-cell transcriptomes.BMC neuroscience · 2024Article
- Whole-body metabolic modelling reveals microbiome and genomic interactions on reduced urine formate levels in Alzheimer's disease.Scientific reports · 2024Article
- Treatment of Alzheimer's Disease in the New Era of Monoclonal Antibodies Against Cerebral Amyloid-β: Pharmacological Prescription and Knowledge in Argentina.Journal of Alzheimer's disease reports · 2024Article
- Metabolic Syndrome: A Narrative Review from the Oxidative Stress to the Management of Related Diseases.Antioxidants (Basel, Switzerland) · 2023Review
- Rescue of Alzheimer's disease phenotype in a mouse model by transplantation of wild-type hematopoietic stem and progenitor cells.Cell reports · 2023Article
- An Update on Apathy in Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2023Review
- Brain electrophysiological recording during olfactory stimulation in mild cognitive impairment and Alzheimer disease patients: An EEG dataset.Data in brief · 2023Article
- The methodology of the Agile Nudge University.Frontiers in health services · 2023Article
- Prevalence of Instrumental Activities of Daily Living Difficulties and Associated Cognitive Predictors Across Racial/Ethnic Groups: Findings From the KHANDLE Study.The journals of gerontology. Series B, Psychological sciences and social sciences · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) patients suffer progressive cognitive, behavioral and functional impairment which result in a heavy burden to patients, families, and the public-health system. AD entails both direct and indirect costs. Indirect costs (such as loss or reduction of income by the patient or family members) are the most important costs in early and community-dwelling AD patients. Direct costs (such as medical treatment or social services) increase when the disorder progresses, and the patient is institutionalized or a formal caregiver is required. Drug therapies represent an increase in direct cost but can reduce some other direct or indirect costs involved. Several studies have projected overall savings to society when using drug therapies and all relevant cost are considered, where results depend on specific patient and care setting characteristics. Dementia should be the focus of analysis when public health policies are being devised. South American countries should strengthen their policy and planning capabilities by gathering more local evidence about the burden of AD and how it can be shaped by treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.